Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study

Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study

BackgroundProgrammed death-1 (PD-1) inhibitors plus tyrosine kinase inhibitors (TKIs) combination therapy are considered as a first-line treatment recommendation for advanced hepatocellular carcinoma (HCC). However, patients with hyperbilirubinemia are excluded from this therapeutic option due to li...

Full description

Saved in:
Bibliographic Details
Main Authors: Shida Pan, Jianing Wang, Jiahe Tian, Yilin Wang, Siyu Wang, Yingying Yu, Fengyi Li, Yan-Mei Jiao, Yingjuan Shen, Luo Yang, Xiaomeng Liu, Qin Qiu, Junqing Luan, Fu-Sheng Wang, Fanping Meng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
hyperbilirubinemia
programmed death 1
immunotherapy
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530477/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items